Literature DB >> 22514264

Clinical predictors of community-genotype ST72-methicillin-resistant Staphylococcus aureus-SCCmec type IV in patients with community-onset S. aureus infection.

Eun-Jeong Joo1, Doo Ryeon Chung, Young Eun Ha, So Yeon Park, Hyun Ah Kim, Min Hee Lim, So Hyun Kim, Cheol-In Kang, Nam Yong Lee, Kwan Soo Ko, Kyong Ran Peck, Jae-Hoon Song.   

Abstract

OBJECTIVES: Community-genotype methicillin-resistant Staphylococcus aureus (MRSA) clones have emerged in the community worldwide and recently have been spreading into the hospitals. To identify predictors of sequence type 72-MRSA-SCCmec type IV (ST72-MRSA-IV) in patients with community-onset (CO) S. aureus infection, a case-control study was conducted among CO S. aureus infections, including healthcare-associated infections.
METHODS: Eighty-four patients with CO infections caused by ST72-MRSA-IV strains in Korea between 2007 and 2009 were selected as cases. Members of the control group were those with CO methicillin-susceptible S. aureus infections and they were matched by the admission date in a 1 : 1 ratio.
RESULTS: The most common type of infection was skin and soft tissue infection in both groups (48.8% versus 52.4%), followed by pneumonia. Female sex (OR 2.55, 95% CI 1.30-5.04), severe sepsis or septic shock (OR 3.05, 95% CI 1.09-8.55), prior hospitalization within the previous year (OR 2.18, 95% CI 1.10-4.32) and surgical site infection (SSI) (OR 4.63, 95% CI 1.38-15.59) were associated with ST72-MRSA-IV infections in multivariate analyses.
CONCLUSIONS: Female sex, SSI, severe sepsis or septic shock and prior hospitalization within the previous year were predictors of ST72-MRSA-IV among patients with CO S. aureus infection.

Entities:  

Mesh:

Year:  2012        PMID: 22514264     DOI: 10.1093/jac/dks120

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  6 in total

1.  First case report of vancomycin-intermediate sequence type 72 Staphylococcus aureus with nonsusceptibility to daptomycin.

Authors:  Ayaka Tsukimori; Itaru Nakamura; Sakiko Okamura; Akihiro Sato; Shinji Fukushima; Yasutaka Mizuno; Tetsuo Yamaguchi; Tetsuya Matsumoto
Journal:  BMC Infect Dis       Date:  2014-08-23       Impact factor: 3.090

2.  Emergence of Community-Genotype Methicillin-Resistant Staphylococcus aureus in Korean Hospitals: Clinical Characteristics of Nosocomial Infections by Community-Genotype Strain.

Authors:  Eun Jeong Joo; Doo Ryeon Chung; So Hyun Kim; Jin Yang Baek; Nam Yong Lee; Sun Young Cho; Young Eun Ha; Cheol In Kang; Kyong Ran Peck; Jae Hoon Song
Journal:  Infect Chemother       Date:  2017-05-26

3.  Ten-Year Prevalence Trends of Phenotypically Identified Community-Associated Methicillin-Resistant Staphylococcus aureus Strains in Clinical Specimens.

Authors:  So Hyun Yu; Jeong Hyun Lee; Min-Chul Kim; Seong-Ho Choi; Jin-Won Chung; Mi-Kyung Lee
Journal:  Ann Lab Med       Date:  2021-07-01       Impact factor: 3.464

4.  Clinical and Microbiological Characteristics of Hospital-Acquired Methicillin-Resistant Staphylococcus aureus Bacteremia Caused by a Community-Associated PVL-Negative Strain.

Authors:  Yun Woo Lee; Seongman Bae; Eunmi Yang; Hyemin Chung; Eunsil Kim; Jiwon Jung; Min Jae Kim; Yong Pil Chong; Sung-Han Kim; Sang-Ho Choi; Sang-Oh Lee; Yang Soo Kim
Journal:  Open Forum Infect Dis       Date:  2021-08-16       Impact factor: 3.835

5.  Clinical and epidemiological factors associated with methicillin resistance in community-onset invasive Staphylococcus aureus infections: prospective multicenter cross-sectional study in Korea.

Authors:  Eu Suk Kim; Hong Bin Kim; Gayeon Kim; Kye-Hyung Kim; Kyung-Hwa Park; Shinwon Lee; Young Hwa Choi; Jongyoun Yi; Chung Jong Kim; Kyoung-Ho Song; Pyoeng Gyun Choe; Nam-Joong Kim; Yeong-Seon Lee; Myoung-Don Oh
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

Review 6.  Community-Acquired Pneumonia in the Asia-Pacific Region.

Authors:  Jae-Hoon Song; Kyungmin Huh; Doo Ryeon Chung
Journal:  Semin Respir Crit Care Med       Date:  2016-12-13       Impact factor: 3.119

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.